Department of Pathology, HELIOS Clinic Bad Saarow, Charité-University Medicine Teaching Hospital, DE-15526 Bad Saarow, Germany.
Pathobiology. 2009;76(6):286-92. doi: 10.1159/000245894. Epub 2009 Nov 30.
Incidental prostate cancer (IPC) has a substantially variable clinical course which cannot be predicted by conventional histopathologic examination of transurethral resection specimens of the prostate (TURP chips). Therefore, efforts should be directed towards defining the natural history of individual IPC. Recently, expression of CD44s (standard isoform), a transmembranous glycoprotein, has been linked to prognostic outcome in prostate cancer, but its prognostic role in IPC has been neglected so far.
We present a multicentre study which evaluates immunohistochemically the largest cohort of IPC patients to date, aiming to correlate CD44s expression in the TURP chips with histopathologic outcome parameters (Gleason scores and histologic staging) performed on subsequent radical prostatectomies (RPs) in a cohort of 54 patients who underwent prostatectomy due to IPC.
CD44s expression recorded in the TURP chips showed a stronger (inverse) association with Gleason scores performed on the corresponding RPs than did other conventional prognostic variables and, therefore, might become a valuable adjunct to better predict outcome in IPC prior to radical prostatectomy.
Advanced prospective studies should aim to define cut-point values of CD44s expression for separating aggressive tumours from their indolent counterparts, and should also assess possible associations with clinical follow-up data (e.g. progression-free survival) in IPC.
偶然发现的前列腺癌(IPC)具有明显不同的临床病程,无法通过经尿道前列腺切除术(TURP)标本的常规组织病理学检查(TURP 芯片)来预测。因此,应努力确定个体 IPC 的自然病史。最近,跨膜糖蛋白 CD44s(标准同工型)的表达与前列腺癌的预后结果相关,但迄今为止,其在 IPC 中的预后作用尚未得到重视。
我们进行了一项多中心研究,评估了迄今为止最大的 IPC 患者队列的免疫组织化学,旨在将 TURP 芯片中的 CD44s 表达与后续根治性前列腺切除术(RP)上的组织病理学结果参数(Gleason 评分和组织学分期)相关联。在因 IPC 而行前列腺切除术的 54 例患者的队列中进行了研究。
与其他常规预后变量相比,TURP 芯片中记录的 CD44s 表达与相应 RP 上的 Gleason 评分呈更强的(负相关),因此可能成为在接受根治性前列腺切除术之前更好地预测 IPC 结果的有价值的辅助手段。
前瞻性研究应旨在确定 CD44s 表达的切点值,以区分侵袭性肿瘤与其惰性对应物,并应评估与 IPC 的临床随访数据(例如无进展生存期)的可能关联。